Abstract: The present invention relates to a fragmented GRS polypeptide and a variant thereof, and a use thereof and, more specifically, to: an isolated polypeptide consisting of 8 to 170 consecutive amino acids including amino acids 531 to 538 in the amino acid sequence represented by SEQ ID NO: 1 or a polypeptide consisting of a variant having a sequence homology of 80% or more with the polypeptide; a fusion protein and a complex comprising the polypeptide; a polynucleotide coding for the polypeptide; and a use thereof for the prevention and treatment of neoplastic diseases, the detection of cancer cells, imaging, and drug delivery.

Abstract: The present invention relates to a peptide for treating inflammation and wounds and, more specifically, to use of a peptide for treating inflammation and wounds, wherein the peptide binds to collagen type VII exposed by damage to tissue and recognizes collagen type VII as an antigen, thereby inhibiting the induction of an immune response, and thus having a function of inhibiting inflammation caused by an autoimmune response, and has the function of promoting wound healing by promoting cell proliferation and migration to a wound site in the damaged tissue. The peptide according to the present invention has the binding ability to collagen type VII, and thus inhibits an immune response caused by collagen type VII, thereby inhibiting inflammation caused by an autoimmune response.

Abstract: The present invention relates to a novel use of a peptide for inhibiting the functions and expressions of multiple disease biomarkers, and more specifically, to a pharmaceutical composition for treating or preventing inflammation, metabolic diseases or fibrotic diseases, the composition comprising any one or more peptide among peptides which are represented by the amino acid sequences of SEQ ID NOs: 1 to 8 have the functions of inhibiting HDAC5 phosphorylation, the expression of the GDF15 protein, and the expression of the ATF3 protein. The peptide, according to the present invention, enables the triple-blocking of the biomarkers associated with inflammation, metabolic diseases or fibrotic diseases by inhibiting HDAC phosphorylation, inhibiting the expression of the GDF15 protein and inhibiting the expression of the ATF3 protein, and thus the production of inflammatory cytokine may be reduced, and thus the peptide is effective in preventing and treating inflammatory, metabolic or fibrotic diseases.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing gingivoperiodontitis or peri-implantitis, comprising, as effective components, sodium ethylenediaminetetra acetate, cetylpyridinium chloride, octyl phenol ethoxylate, and sodium bicarbonate. The composition according to the present invention can effectively eliminate bacteria causing gingivoperiodontitis and peri-implantitis, thereby alleviating inflammation, and furthermore, an interdental brush coated with the composition is convenient to apply to gaps between teeth, dental implants, orthodontic appliances, etc. and thus can be used to treat and prevent gingivoperiodontitis and peri-implantitis conveniently at home.

Abstract: The present invention relates to a GRP78-derived peptide for screening highly efficient stem cells and the use thereof, and more particularly, to screening highly efficient stem cells using, as a marker, a GRP78-derived peptide capable of binding to the binding domain of GRP78 protein on the cell surface. According to the present invention, the GRP78-derived peptide comprising only a specific amino acid sequence capable of recognizing highly efficient stem cells, among the amino acid sequence of GRP78, makes it possible to screen only non-senescent young stem cells. In addition, when stem cells are treated with the GRP78-derived peptide or the GRP78-derived peptide is introduced into stem cells, the efficiency of the stem cells can be increased. Thus, the GRP78-derived peptide is useful for the production of stem cell therapy products having excellent efficacy.

Abstract: The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases.

Abstract: The present invention relates to: a composition for inhibiting biofilms, containing, as an active ingredient, a peptide derived from human ?-defensin-3; and a method for inhibiting biofilms by using the composition. The peptide according to the present invention inhibits bacterial biofilms even when used alone and exhibits a remarkably increased biofilm inhibitory effect when used in combination with a conventional dental therapeutic agent, and has an effect of preventing a tooth discoloration side effect caused by a conventional dental therapeutic agent.